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Ethnopharmacology and Traditional 
Herbal Medicine
Over the past two decades, traditional medicine, 
now termed “Complementary and Alternative Medicine 
(CAM)” in the medical community, has been attracting 
considerable attention. CAM has opened an important 
genre of the comprehensive and integrative health care 
provision and health sector reform. An essential part 
of CAM includes practice of herbal medicine which 
employs diverse botanical formulations with distinct 
pharmacological properties. Plant-derived substances 
have been the mainstay of traditional medicine and 
represent a principal components of the modern 
pharmaceuticals as well. In reality, drugs derived 
from natural product resources, especially those in 
plant kingdom, are of immense importance in terms 
of their potential applications for the management of 
a multiplicity of human disorders. Thus, a substantial 
proportion of all  prescriptions dispensed from 
community pharmacies in the world contain one or 
more ingredients derived from higher plants. It is 
estimated that approximately 80% of the world’s 
population depends exclusively on plants for their health 
and healing. In the area of cancer over the time frame 
around 1940s to 2007, of the 155 small molecules, 73% 
are non-synthetic, with 47% actually being either natural 
products or directly derived therefrom (Newman and 
Cragg, 2007).
A wide array of  modern drugs included the 
international pharmacopoeia have an origin in 
ethnopharmacology and traditional herbal medicine. 
Numerous plant extracts and their ingredients have 
unique pharmacological activities, such as anti-
inflammatory, anti-diabetic,  anti-carcinogenic, 
vasodilatory, anti-bacterial, anti-viral, anticonvulsant, 
sedative and antipyretic effects. However, very few 
randomized-controlled studies have been carried out 
to precisely evaluate their therapeutic efficacy and 
safety. Nonetheless, for some of the botanical materials, 
there are relatively well-organized database available 
describing the therapeutic potential, and their active 
ingredients can be tested by exploiting modern scientific 
methods (Patwardhan and Vaidya, 2010). 
In the early days of pharmacology, therapeutic drugs 
were often discovered incidentally from medicinal 
plants as part of folk remedy. These desirable accidental 
discoveries are referred to as drug serendipity 
(Takenaka, 2001). There are many examples of 
medicinal plants and their constituents that have 
provided serendipitous bedside observations. Such 
clinical hits can be a basis of drug discovery and 
development. Advances in combinatorial chemistry 
and systems biology have created many drugable new 
entities. 
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Paradigm Shift for Modern Drug 
Development: Reversing the Path
Biotechnological advances, including high throughput 
screening or combinatorial and asymmetric synthesis, 
have opened new vitas in drug discovery. Nonetheless, 
the industry is facing serious challenges as the drug 
discovery process has become extremely expensive, 
riskier and critically inefficient. Post-marketing failures 
of blockbuster drugs and a serious innovation deficit 
are major concerns of big Pharmas. Consequently, there 
has been a remarkable shift in favor of single- to multi-
targeted drugs, expecially for polygenic syndrome, 
based on knowledge from traditional medicine. 
Strategic options based on natural product drug 
discovery, ethnopharmacology and traditional medicines 
are re-emerging as an alternative discovery engine 
(Patwardhan and Vaidya, 2010). Scientifically validated 
and technologically standardized botanical products may 
be explored on a fast track using innovative approaches 
(Patwardhan et al., 2008). This offers an efficient 
development platform for herbal formulations, which 
expedites the process for the botanical drug discovery 
and development by reducing and economizing 
investments (Patwardhan and Vaidy, 2010).
A trans-disciplinary endeavor called reverse 
pharmacology has recently emerged and this new 
academic discipline can reduce three major bottlenecks- 
cost, time, and toxicity- frequently encountered in 
conventional drug development. Reverse pharmacology 
offers a major paradigm shift in drug discovery. 
Instead of serendipitous findings pursued randomly, an 
organized path from clinical experiences, experimental 
observations and data base has been established 
(Patwardhan et al., 2008). Traditional knowledge and 
clinical observations, combined with powerful modern 
technologies revolutionize the whole process of drug 
discovery, design and development.
Reverse Pharmacology
Reverse pharmacology integrates documented 
serendipitous clinical and experimental hits into leads 
that are further developed into drug candidates or 
formulations through more systematic and precisely 
designed preclinical and clinical research. A salient 
feature of this approach is the combination of 
knowledge learned from traditional or folk medicine 
and the modern technology to provide better and 
safer leads (Patwardhan and Mashelkar, 2009). The 
endeavor to study well-documented findings would 
facilitate not only identification of candidate drugs 
but also understanding of their underlying molecular 
mechanisms.
Drug screening using the classical pharmacological 
methods is time-consuming and inefficient. Using 
current technology and genomics, proteomics and 
metabolomics, scientists now move in the opposite 
direction to that used in conventional pharmacological 
research for new drug development. This strategy, 
referred to as “reverse pharmacology”, has many 
advantages. The drug development process with reverse 
pharmacological approach is much faster (< 5 years) 
and more efficient than that achievable with the classical 
approach, which often requires the decade-long time to 
launch (Takenaka, 2001). 
Reverse pharmacology can be perceived to comprise 
of three domains. The first one is the experiential 
phase that includes documentation of robust clinical 
observations of the biodynamic effects of formulations 
used in folk medicine or already developed drug 
formulations and their precursors by meticulous 
record keeping. Second, the exploratory studies for 
tolerability, drug-interactions, dose-range finding in 
ambulant patients with defined subsets of the disease 
and para-clinical studies using relevant in vitro and in 
vivo models to evaluate the target-activity. Third phase 
includes experimental studies, basic and clinical, at 
several levels of biological organization, to identify and 
validate reverse pharmacological correlates of safety and 
efficacy of drug candidates. The traditional knowledge-
inspired reverse pharmacology relates to reversing the 
routine “laboratory-to-clinic” path of drug discovery 
pipeline to “clinic-to-laboratories” (Patwardhan et al., 
2008) 
Conclusion and Future Perspectives 
Drug discovery strategies based on natural products 
and traditional medicines are re-emerging as attractive 
options. The R&D thrust in many pharmaceutical 
sectors has focused on development of botanical drugs 
through investigation of leads from the traditional 
herbal medicine. Herbs are of great importance as a 
reservoir of chemical diversity and can be explored for 
discovery of potential drug candidates. Knowledge and 
experimental database of traditional herbal medicine 
can provide new functional leads to reduce time, money 
and toxicity – the three main hurdles in the conventional 
drug development. A reverse pharmacology approach, 
inspired by traditional medicine, can offer a rational 
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and pragmatic strategy for identification of new drug 
candidates. Reverse pharmacological approaches rely 
primarily on clinical experiences, observations or 
available data on actual use in patients as a starting 
point. This trans-disciplinary science also adopts 
principles of systems biology where holistic yet 
rational analysis is done to address multiple therapeutic 
requirements. Since safety of the materials has already 
been established from traditional use track record, 
pharmaceutical development, safety validation and 
pharmacodynamic studies can be conducted in parallel 
to controlled cinical studies. Thus, drug discovery 
based on the reverse pharmacology follows a path from 
clinics to laboratories, an opposite direction applied for 
conventional synthetic drug development (Patwardhan 
et al., 2008) 
Legacy of traditional wisdom, modern Western 
medicine and high throughput technology converge to 
form a golden triangle. By bringing all these together, 
reverse pharmacology can accelerate the development 
of innovative drugs with excellent efficacy with minimal 
toxicity.
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